Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
Immunic (Nasdaq: IMUX) has announced the pricing of a $5.1 million registered direct offering of common stock, led by Aberdeen Investments. The company is offering 5,666,667 shares at $0.90 per share.
The biotechnology company, which develops oral small molecule therapies for chronic inflammatory and autoimmune diseases, expects to close the offering around April 10, 2025. The net proceeds will be used to fund clinical trials, operations, and general corporate purposes.
Titan Partners Group, a division of American Capital Partners, is serving as the sole placement agent for this offering, which is being conducted under a previously filed shelf registration statement that became effective on May 31, 2024.
Immunic (Nasdaq: IMUX) ha annunciato il prezzo di un offerta diretta registrata di 5,1 milioni di dollari di azioni ordinarie, guidata da Aberdeen Investments. L'azienda offre 5.666.667 azioni a 0,90 dollari per azione.
La società biotecnologica, che sviluppa terapie a piccole molecole orali per malattie infiammatorie croniche e autoimmuni, prevede di chiudere l'offerta intorno al 10 aprile 2025. I proventi netti saranno utilizzati per finanziare studi clinici, operazioni e scopi aziendali generali.
Titan Partners Group, una divisione di American Capital Partners, funge da unico agente di collocamento per questa offerta, che viene condotta sotto una dichiarazione di registrazione di shelf precedentemente depositata che è diventata efficace il 31 maggio 2024.
Immunic (Nasdaq: IMUX) ha anunciado el precio de una oferta directa registrada de 5,1 millones de dólares de acciones ordinarias, liderada por Aberdeen Investments. La compañía está ofreciendo 5.666.667 acciones a 0,90 dólares por acción.
La empresa biotecnológica, que desarrolla terapias de pequeñas moléculas orales para enfermedades inflamatorias crónicas y autoinmunitarias, espera cerrar la oferta alrededor del 10 de abril de 2025. Los ingresos netos se utilizarán para financiar ensayos clínicos, operaciones y fines corporativos generales.
Titan Partners Group, una división de American Capital Partners, actúa como único agente de colocación para esta oferta, que se realiza bajo una declaración de registro de shelf presentada anteriormente que se volvió efectiva el 31 de mayo de 2024.
Immunic (Nasdaq: IMUX)는 Aberdeen Investments가 주도하는 510만 달러 규모의 등록 직접 공모 가격을 발표했습니다. 이 회사는 5,666,667주를 주당 0.90달러에 제공합니다.
만성 염증 및 자가면역 질환을 위한 경구용 소분자 치료제를 개발하는 생명공학 회사는 2025년 4월 10일 경에 공모를 마감할 것으로 예상하고 있습니다. 순수익은 임상 시험, 운영 및 일반 기업 목적에 사용될 것입니다.
American Capital Partners의 부서인 Titan Partners Group은 이 공모의 단독 배치 에이전트로 활동하고 있으며, 이는 2024년 5월 31일에 효력이 발생한 이전에 제출된 선반 등록 성명서에 따라 진행되고 있습니다.
Immunic (Nasdaq: IMUX) a annoncé le prix d'une offre directe enregistrée de 5,1 millions de dollars d'actions ordinaires, dirigée par Aberdeen Investments. La société propose 5.666.667 actions à 0,90 dollar par action.
La société biopharmaceutique, qui développe des thérapies à petites molécules orales pour les maladies inflammatoires chroniques et auto-immunes, prévoit de clôturer l'offre autour du 10 avril 2025. Le produit net sera utilisé pour financer des essais cliniques, des opérations et des fins générales d'entreprise.
Titan Partners Group, une division d'American Capital Partners, agit en tant qu'agent de placement unique pour cette offre, qui est réalisée dans le cadre d'une déclaration d'enregistrement de shelf précédemment déposée et entrée en vigueur le 31 mai 2024.
Immunic (Nasdaq: IMUX) hat den Preis für ein registriertes Direktangebot über 5,1 Millionen Dollar von Stammaktien bekannt gegeben, das von Aberdeen Investments geleitet wird. Das Unternehmen bietet 5.666.667 Aktien zu einem Preis von 0,90 Dollar pro Aktie an.
Das Biotechnologieunternehmen, das orale kleine Molekültherapien für chronische Entzündungs- und Autoimmunerkrankungen entwickelt, erwartet, das Angebot um den 10. April 2025 abzuschließen. Die Nettoerlöse werden zur Finanzierung klinischer Studien, des Betriebs und allgemeiner Unternehmenszwecke verwendet.
Titan Partners Group, eine Division von American Capital Partners, fungiert als alleiniger Platzierungsagent für dieses Angebot, das unter einer zuvor eingereichten Shelf-Registrierungsanmeldung durchgeführt wird, die am 31. Mai 2024 wirksam wurde.
- Secured $5.1 million in additional funding
- Investment led by institutional investor Aberdeen Investments
- Offering price of $0.90 per share indicates significant discount to previous trading levels
- Substantial dilution for existing shareholders with 5.67M new shares
- Small offering size of $5.1M may not provide long-term funding security
Insights
Immunic's $5.1 million registered direct offering represents a modest capital raise that will result in approximately
For a clinical-stage biotech with an
The stated use of proceeds for clinical trials and operations indicates continued advancement of Immunic's inflammatory and autoimmune disease pipeline rather than merely extending operational timeline. However, the relatively small size of this offering compared to typical clinical development costs suggests this may represent bridge financing to either specific milestones or a larger future capital raise.
While securing additional funding is generally positive for development-stage companies, the modest size and dilutive impact balance each other out. Without specific details on current cash position or burn rate, it's difficult to determine how meaningfully this raise will impact Immunic's operational timeline, but it does provide immediate working capital for continued pipeline advancement in a challenging biotech funding environment.
The gross proceeds from the offering are expected to be approximately
The Company intends to use the net proceeds received from the proposed offering to fund its clinical trials and operations and for other general corporate purposes.
Titan Partners Group, a division of American Capital Partners, is acting as the sole placement agent for the offering.
The offering is being made by Immunic pursuant to a shelf registration statement on Form S-3 (File No. 333-275717) previously filed with the Securities and Exchange Commission (the "SEC") on November 22, 2023, which became effective on May 31, 2024. The offering is being made only by means of a prospectus supplement and the accompanying base prospectus that form a part of the registration statement. A final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Copies of the final prospectus supplement and the accompanying base prospectus relating to the offering, when available, may be obtained by contacting Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 29th Floor,
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2 clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis and moderate-to-severe ulcerative colitis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease as well as inflammatory bowel disease, Graft-versus-Host-Disease and weight management. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: www.imux.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the expected timing of and funding to the company from the registered direct offering; Immunic's development programs and the targeted diseases; the potential for Immunic's development programs to safely and effectively target diseases; interpretation of preclinical and clinical data for Immunic's development programs and potential effects; the timing of current and future clinical trials and anticipated clinical milestones; the nature, strategy and focus of the company and further updates with respect thereto; the development and commercial potential of any product candidates of the company; and the company's expected cash runway. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the
Contact Information
Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com
US Media Contact
KCSA Strategic Communications
Caitlin Kasunich
+1 212 896 1241
ckasunich@kcsa.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/immunic-inc-announces-pricing-of-5-1-million-registered-direct-offering-led-by-aberdeen-investments-302424493.html
SOURCE Immunic, Inc.
FAQ
How much is Immunic (IMUX) raising in their April 2025 offering?
What is the share price and number of shares in IMUX's 2025 offering?
How will Immunic use the proceeds from their 2025 stock offering?
When is IMUX's registered direct offering expected to close?
